Previous 10 | Next 10 |
New research further confirms value of interrogating epigenomic signals with Guardant Infinity™ platform to identify novel biomarker targets and predict treatment resistance Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the company...
2023-05-30 10:55:34 ET Guardant Health ( NASDAQ: GH ) rose 2% amid vague speculation the company could become a target for an activist. Guardant Health ( GH ) may be vulnerable to an activist as its share price has been cut by about 45% in the past six months, according ...
CALGARY, AB / ACCESSWIRE / May 25, 2023 / Gamehost Inc.'s (TSX:GH) (" Gamehost " or the " Corporation ") announced that all of the motions put forward at its annual general meeting of shareholders held on May 9, 2023 were approved by the shareholders. The detailed results of the voting are as fo...
2023-05-23 04:57:28 ET Guardant Health ( NASDAQ: GH ) upsized and priced an offering of 12.5M common shares at $28 apiece to raise ~$350M in gross proceeds. The company previously announced plans to raise ~$250M. Guardant granted the underwriters a 30-day option to buy up ...
Guardant Health, Inc. (Nasdaq:GH), a leading precision oncology company, today announced the pricing of an upsized underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $28.00 per share, before deducting underwriting discounts and commissions. In addi...
2023-05-22 16:50:30 ET Guardant Health ( NASDAQ: GH ) said Monday it intends to offer $250 million of its common stock in an underwritten public offering. Shares -7.5% at 28.50 after hours. The company said it intends to grant the underwriters a 30...
2023-05-19 17:50:00 ET Shares of Guardant Health (NASDAQ: GH) were up 14.4% for the week as of Friday afternoon and rose as much as 15.7% for the week, according to data provided by S&P Global Market Intelligence . The healthcare company specializes in precision oncology...
With new coverage from Anthem Blue Cross and Blue Shield, Aetna and Humana, Guardant360 CDx/Guardant360 liquid biopsy test now covered by all major commercial health insurers Only blood test approved by FDA as companion diagnostic for ORSERDU™ (elacestrant), Guardant360 CDx gai...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the publication of its inaugural Environmental, Social & Governance (ESG) Report, which provides information related to key ESG commitments that the company has laid out as part of its business strategy....
2023-05-11 16:50:41 ET Shares of Guardant Health (NASDAQ: GH) were up 14.8% for the week as of Thursday afternoon and rose as much as 19.8% for the week, according to data provided by S&P Global Market Intelligence . The healthcare stock, which focuses on oncology diagno...
News, Short Squeeze, Breakout and More Instantly...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...
2024-07-21 23:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...